Stockreport

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with expected up to six-month review period In Phase 2 urticaria clinical t [Read more]